Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06952517

Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea

Efficacy and Safety of Topical Clascoterone Cream 1% in Patients With Facial Acneiform Rosacea

Status
Recruiting
Phase
Phase 2
Study type
Interventional
Enrollment
20 (estimated)
Sponsor
Narrows Institute for Biomedical Research · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

To demonstrate the efficacy of Clascoterone cream 1% in reducing the size of sebaceous glands in study participants with acneiform rosacea.

Conditions

Interventions

TypeNameDescription
DRUGClascoterone Cream 1%Clascoterone 1% cream

Timeline

Start date
2025-03-14
Primary completion
2025-09-01
Completion
2025-09-30
First posted
2025-05-01
Last updated
2025-05-06

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT06952517. Inclusion in this directory is not an endorsement.

Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea (NCT06952517) · Clinical Trials Directory